Browsing Tag
ESMO 2024
3 posts
Nuvalent’s stock jumps 22% after ESMO 2024 – what’s next for this biotech game-changer?
Nuvalent, Inc., a biopharmaceutical company specialising in targeted cancer therapies, has seen its stock price skyrocket following the…
New data from Incyte highlights efficacy of CDK2 inhibitor in ovarian cancer; Pivotal trials expected in 2025
Incyte has announced new early-stage clinical data for INCB123667, a highly selective and potential first-in-class CDK2 inhibitor, showing…
Agenus announces promising trial results for colon cancer treatment at ESMO Congress
Agenus Inc. (Nasdaq: AGEN), a pioneer in the development of immunological agents for cancer treatment, has recently unveiled…